Δημοσίευση

Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.

ΤίτλοςObesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.
Publication TypeJournal Article
Year of Publication2019
AuthorsKatsiki, N., Anagnostis P., Kotsa K., Goulis D. G., & Mikhailidis D. P.
JournalCurr Pharm Des
Volume25
Issue18
Pagination2051-2059
Date Published2019
ISSN1873-4286
Λέξεις κλειδιάCardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Metabolic syndrome, Non-alcoholic Fatty Liver Disease, Obesity, Risk Factors
Abstract

BACKGROUND: Obesity frequently co-exists with type 2 diabetes mellitus (T2DM), leading to the socalled "diabesity epidemic". The metabolic syndrome (MetS), a cluster of central obesity, hypertension, dysglycemia, insulin resistance and/or atherogenic dyslipidemia, as well as non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of MetS, has been associated with increased cardiovascular disease (CVD), T2DM and chronic kidney disease (CKD) incidence. However, the association between obesity, MetS (including NAFLD) and diabetic microvascular complications is less evident.
METHODS: The present narrative review discusses the associations of obesity, MetS and NAFLD with diabetic kidney disease (DKD), diabetic retinopathy (DR) and diabetic peripheral neuropathy (DPN) as well as cardiac autonomic neuropathy (CAN). The available data on the effects of lifestyle measures and bariatric surgery on these diabetic complications are also briefly discussed.
RESULTS: Overall, both obesity and MetS have been related to DKD, DR and DPN, although conflicting results exist. Links between NAFLD and diabetic microvascular complications have also been reported but data are still limited. Lifestyle intervention and bariatric surgery may prevent the development and/or progression of these microvascular complications but more evidence is needed.
CONCLUSION: Clinicians should be aware of the frequent co-existence of MetS and/or NAFLD in T2DM patients to prevent or treat these metabolic disorders, thus potentially minimizing the risk for both CVD and diabetic microvascular complications.

DOI10.2174/1381612825666190708192134
Alternate JournalCurr Pharm Des
PubMed ID31298151

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.